Cargando…

Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma

BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yu-Ting, Wu, Shuang-Yue, Yang, Song, Ying, Jie, Tian, Lu, Xu, Hong-Liang, Zhang, He-Ping, Yao, Hui, Zhang, Wei-Yu, Jin, Qin-Qin, Yang, Yin-Ting, Jiang, Xi-Ya, Zhang, Nan, Yao, Shun, Zhou, Shu-Guang, Chen, Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404752/
https://www.ncbi.nlm.nih.gov/pubmed/37554782
http://dx.doi.org/10.1016/j.heliyon.2023.e18708
_version_ 1785085368168611840
author Zhu, Yu-Ting
Wu, Shuang-Yue
Yang, Song
Ying, Jie
Tian, Lu
Xu, Hong-Liang
Zhang, He-Ping
Yao, Hui
Zhang, Wei-Yu
Jin, Qin-Qin
Yang, Yin-Ting
Jiang, Xi-Ya
Zhang, Nan
Yao, Shun
Zhou, Shu-Guang
Chen, Guo
author_facet Zhu, Yu-Ting
Wu, Shuang-Yue
Yang, Song
Ying, Jie
Tian, Lu
Xu, Hong-Liang
Zhang, He-Ping
Yao, Hui
Zhang, Wei-Yu
Jin, Qin-Qin
Yang, Yin-Ting
Jiang, Xi-Ya
Zhang, Nan
Yao, Shun
Zhou, Shu-Guang
Chen, Guo
author_sort Zhu, Yu-Ting
collection PubMed
description BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OSC, however, has only been the topic of a few studies. METHODS: The mRNA sequencing and clinical information of OSC came from The Cancer Genome Atlas Target Genotype-Tissue Expression (TCGA TARGET GTEx) dataset. Anoikis-related genes (ARGs) were collected by Harmonizome and GeneCards websites. Centered on these ARGs, we used unsupervised consensus clustering to explore potential tumor typing and filtered hub ARGs to create a model of predictive signature for OSC patients. Furthermore, we presented clinical specialists with a novel nomogram based on ARGs, revealing the underlying clinical relevance of this signature. Finally, we explored the immune microenvironment among various risk groups. RESULTS: We identified 24 ARGs associated with the prognosis of OSC and classified OSC patients into three subtypes, and the subtype with the best prognosis was more enriched in immune-related pathways. Seven ARGs (ARHGEF7, NOTCH4, CASP2, SKP2, PAK4, LCK, CCDC80) were chosen to establish a risk model and a nomogram that can provide practical clinical decision support. Risk scores were found to be an independent and significant prognostic factor in OSC patients. The CIBERSORTx result revealed an inflammatory microenvironment is different for risk groups, and the proportion of immune infiltrates of Macrophages M1 is negatively correlated with risk score (r(s) = −0.21, P < 0.05). Ultimately, quantitative reverse transcription polymerase chain reaction (RT-PCR) was utilized to validate the expression of the seven pivotal ARGs. CONCLUSION: In this study, based on seven ARGs, a risk model and nomogram established can be used for risk stratification and prediction of survival outcomes in patients with OSC, providing a reliable reference for individualized therapy of OSC patients.
format Online
Article
Text
id pubmed-10404752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104047522023-08-08 Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma Zhu, Yu-Ting Wu, Shuang-Yue Yang, Song Ying, Jie Tian, Lu Xu, Hong-Liang Zhang, He-Ping Yao, Hui Zhang, Wei-Yu Jin, Qin-Qin Yang, Yin-Ting Jiang, Xi-Ya Zhang, Nan Yao, Shun Zhou, Shu-Guang Chen, Guo Heliyon Research Article BACKGROUND: Ovarian serous cystadenocarcinoma (OSC) is the most prevalent histological subtype of ovarian cancer (OV) and presents a serious threat to women's health. Anoikis is an essential component of metastasis, and tumor cells can get beyond it to become viable. The impact of anoikis on OSC, however, has only been the topic of a few studies. METHODS: The mRNA sequencing and clinical information of OSC came from The Cancer Genome Atlas Target Genotype-Tissue Expression (TCGA TARGET GTEx) dataset. Anoikis-related genes (ARGs) were collected by Harmonizome and GeneCards websites. Centered on these ARGs, we used unsupervised consensus clustering to explore potential tumor typing and filtered hub ARGs to create a model of predictive signature for OSC patients. Furthermore, we presented clinical specialists with a novel nomogram based on ARGs, revealing the underlying clinical relevance of this signature. Finally, we explored the immune microenvironment among various risk groups. RESULTS: We identified 24 ARGs associated with the prognosis of OSC and classified OSC patients into three subtypes, and the subtype with the best prognosis was more enriched in immune-related pathways. Seven ARGs (ARHGEF7, NOTCH4, CASP2, SKP2, PAK4, LCK, CCDC80) were chosen to establish a risk model and a nomogram that can provide practical clinical decision support. Risk scores were found to be an independent and significant prognostic factor in OSC patients. The CIBERSORTx result revealed an inflammatory microenvironment is different for risk groups, and the proportion of immune infiltrates of Macrophages M1 is negatively correlated with risk score (r(s) = −0.21, P < 0.05). Ultimately, quantitative reverse transcription polymerase chain reaction (RT-PCR) was utilized to validate the expression of the seven pivotal ARGs. CONCLUSION: In this study, based on seven ARGs, a risk model and nomogram established can be used for risk stratification and prediction of survival outcomes in patients with OSC, providing a reliable reference for individualized therapy of OSC patients. Elsevier 2023-07-26 /pmc/articles/PMC10404752/ /pubmed/37554782 http://dx.doi.org/10.1016/j.heliyon.2023.e18708 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Zhu, Yu-Ting
Wu, Shuang-Yue
Yang, Song
Ying, Jie
Tian, Lu
Xu, Hong-Liang
Zhang, He-Ping
Yao, Hui
Zhang, Wei-Yu
Jin, Qin-Qin
Yang, Yin-Ting
Jiang, Xi-Ya
Zhang, Nan
Yao, Shun
Zhou, Shu-Guang
Chen, Guo
Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title_full Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title_fullStr Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title_full_unstemmed Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title_short Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
title_sort identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404752/
https://www.ncbi.nlm.nih.gov/pubmed/37554782
http://dx.doi.org/10.1016/j.heliyon.2023.e18708
work_keys_str_mv AT zhuyuting identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT wushuangyue identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT yangsong identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT yingjie identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT tianlu identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT xuhongliang identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT zhangheping identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT yaohui identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT zhangweiyu identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT jinqinqin identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT yangyinting identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT jiangxiya identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT zhangnan identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT yaoshun identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT zhoushuguang identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma
AT chenguo identificationandvalidationofanovelanoikisrelatedsignatureforpredictingprognosisandimmunelandscapeinovarianserouscystadenocarcinoma